{"id":389309,"date":"2022-12-28T00:00:00","date_gmt":"2022-12-28T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2022-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2022\/"},"modified":"2026-03-31T10:35:28","modified_gmt":"2026-03-31T10:35:28","slug":"dlsfon0006-2022-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2022","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/dlsfon0006-2022-biopharma-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia-disease-landscape-and-forecast-g7-2022\/","title":{"rendered":"Non-Hodgkin&#8217;s Lymphoma and Chronic Lymphocytic Leukemia | Disease Landscape and Forecast | G7 | 2022"},"content":{"rendered":"<p>The launch of several novel therapies, as well as multiple label expansions of premium-priced agents, will fuel significant growth of the non-Hodgkin\u2019s lymphoma (NHL) \/ chronic lymphocytic leukemia (CLL) therapy market. Key therapies expected to fuel growth are the CAR T-cell therapies Yescarta (Gilead), Kymriah (Novartis), Tecartus (Gilead), and Breyanzi (Bristol Myers Squibb), targeted agents Polivy (Roche), Monjuvi \/ Minjuvi (MorphoSys \/ Incyte), Tazverik (Epizyme), Brukinsa (BeiGene), Zynlonta (ADC Therapeutics), as well as the approval of first-in-class bispecific antibody, Lunsumio (Roche). In addition, combinations incorporating Imbruvica (Janssen \/ AbbVie), Calquence (AstraZeneca), and Venclexta \/ Venclyxto (AbbVie \/ Roche) will enter the CLL market, resulting in a shift away from conventional immunochemotherapy regimens. Notably, the anticipated launch of the other bispecific antibodies glofitamab (Roche) and epcoritamab (Genmab \/ AbbVie) and the noncovalent BTK inhibitor pirtobrutinib (Loxo Oncology \/ Eli Lilly) will further fragment the DLBCL, FL, and CLL \/ SLL patient settings, creating intense competition.<\/p>\n<p><strong>Questions Answered<\/strong><\/p>\n<ul>\n<li>What is the size of clinically and commercially relevant drug-treatable NHL \/ CLL populations, and how will drug-treatment rates change over the 2021-2031 forecast period, by geography?<\/li>\n<li>What is the expected market impact of recent drug approvals and label expansions on the various NHL \/ CLL patient populations?<\/li>\n<li>Which emerging therapies are the most promising in NHL \/ CLL, and what patient populations will they target? What will be their impact on the NHL \/ CLL market?<\/li>\n<li>What factors are driving growth in the NHL \/ CLL market? Which drug class will dominate the treatment of NHL \/ CLL?<\/li>\n<\/ul>\n<p><strong>Content Highlights<\/strong><\/p>\n<p>Markets covered: United States, France, Germany, Italy, Spain, United Kingdom, Japan.<\/p>\n<p>Primary research: 19 country-specific interviews with experts and 210 country-specific surveys with hematologist-oncologists treating NHL.<\/p>\n<p>Epidemiology: Diagnosed incidence of NHL by country; drug-treatable and drug-treated cases segmented by subtype (follicular lymphoma, diffuse large B-cell lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia \/ small lymphocytic leukemia) and line of therapy.<\/p>\n<p>Population segments in market forecast: First-line, second-line, third-line, and fourth-line for FL, CLL \/ SLL, DLBCL, and MCL.<\/p>\n<p>Emerging therapies: Phase III \/ PR: 11 drugs.<\/p>\n<p><strong>Product Description<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.<\/p>\n<p><strong>Solution Enhancement<\/strong><\/p>\n<p>Disease Landscape &#038; Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.<\/p>\n<p>Additionally, Disease Landscape &#038; Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.<\/p>\n","protected":false},"template":"","class_list":["post-389309","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-hodgkins-lymphoma","biopharma-therapy-areas-non-hodgkins-lymphoma-and-chronic-lymphocytic-leukemia","biopharma-date-960"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389309","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":2,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389309\/revisions"}],"predecessor-version":[{"id":576142,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389309\/revisions\/576142"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389309"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}